Inogen Inc (INGN)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $147.95M
Last updated: Nov 17, 2026 at 11:04 AM ET
Inogen Inc (INGN) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Inogen reported EPS of -$0.56, below the -$0.06 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
INGN's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
INGN Earnings Call
The latest INGN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, INGN beat 30 and missed 10. Revenue for the quarter ended Sep 30, 2026 was $77.19M, down 2.4% from $79.09M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.56 | -$0.06 | -$0.06 - -$0.06 | -833.33% | Miss | N/A | 1 | 0 up, 1 down | Nov 5, 2026 | $77.19M |
| Jun 30, 2026 | -$0.14 | -$0.17 | N/A | +17.65% | Beat | N/A | 1 | 0 up, 0 down | Aug 6, 2026 | $95.08M |
| Mar 31, 2026 | -$0.14 | -$0.21 | -$0.21 - -$0.21 | +33.33% | Beat | N/A | 1 | 0 up, 0 down | May 7, 2026 | $85.11M |
| Dec 31, 2025 | -$0.15 | -$0.34 | N/A | +56.19% | Beat | N/A | 1 | 0 up, 0 down | Feb 24, 2026 | $81.72M |
| Sep 30, 2025 | -$0.20 | -$0.22 | N/A | +9.09% | Beat | N/A | 1 | 0 up, 0 down | Nov 5, 2025 | $79.09M |
| Jun 30, 2025 | -$0.15 | -$0.22 | N/A | +31.82% | Beat | N/A | 1 | 0 up, 0 down | Aug 7, 2025 | $92.28M |
| Mar 31, 2025 | -$0.11 | -$0.25 | -$0.25 - -$0.25 | +56.00% | Beat | N/A | 1 | 0 up, 0 down | May 7, 2025 | $82.28M |
| Dec 31, 2024 | -$0.24 | -$0.49 | -$0.49 - -$0.49 | +51.02% | Beat | N/A | 1 | 0 up, 1 down | Feb 25, 2025 | $80.08M |
| Sep 30, 2024 | -$0.11 | -$0.27 | N/A | +59.26% | Beat | N/A | 4 | 0 up, 0 down | Nov 7, 2024 | $88.83M |
| Jun 30, 2024 | -$0.07 | -$0.39 | N/A | +82.05% | Beat | N/A | 4 | 0 up, 0 down | Aug 6, 2024 | $88.77M |
| Mar 31, 2024 | -$0.45 | -$0.58 | N/A | +22.41% | Beat | N/A | 4 | 0 up, 0 down | May 7, 2024 | $78.03M |
| Dec 31, 2023 | -$1.14 | -$0.62 | -$0.71 - -$0.57 | -83.87% | Miss | N/A | 4 | 0 up, 0 down | Feb 27, 2024 | $75.90M |
| Sep 30, 2023 | -$0.36 | -$0.23 | N/A | -56.52% | Miss | N/A | 4 | 0 up, 0 down | Nov 7, 2023 | $83.97M |
| Jun 30, 2023 | -$0.40 | -$0.60 | -$0.69 - -$0.46 | +33.33% | Beat | N/A | 4 | 0 up, 0 down | Aug 7, 2023 | $83.64M |
| Mar 31, 2023 | -$0.78 | -$0.75 | -$1.01 - -$0.70 | -4.00% | Miss | N/A | 4 | 0 up, 0 down | May 4, 2023 | $72.16M |
| Dec 31, 2022 | -$0.20 | -$0.57 | -$0.70 - -$0.45 | +64.91% | Beat | N/A | 5 | 0 up, 0 down | Feb 23, 2023 | $88.09M |
| Sep 30, 2022 | -$0.42 | -$0.38 | -$0.55 - -$0.30 | -10.53% | Miss | -179.2% | 5 | 0 up, 0 down | Nov 2, 2022 | $105.39M |
| Jun 30, 2022 | -$0.15 | -$0.33 | -$0.44 - -$0.28 | +54.55% | Beat | -168.2% | 5 | 0 up, 0 down | Aug 4, 2022 | $103.38M |
| Mar 31, 2022 | -$0.62 | -$0.51 | -$0.64 - -$0.35 | -21.57% | Miss | N/A | 5 | 0 up, 0 down | May 5, 2022 | $80.39M |
| Dec 31, 2021 | -$1.01 | -$0.73 | -$0.79 - -$0.69 | -38.36% | Miss | N/A | 5 | N/A | Feb 24, 2022 | $76.40M |
| Sep 30, 2021 | $0.53 | -$0.29 | -$0.50 - -$0.10 | +282.76% | Beat | N/A | 6 | N/A | Nov 4, 2021 | $93.11M |
| Jun 30, 2021 | $0.22 | -$0.10 | -$0.17 - $0.22 | +320.00% | Beat | +83.3% | 6 | N/A | Aug 4, 2021 | $101.56M |
| Mar 31, 2021 | -$0.03 | -$0.26 | -$0.35 - -$0.15 | +88.46% | Beat | N/A | 6 | N/A | May 4, 2021 | $86.93M |
| Dec 31, 2020 | -$0.23 | -$0.26 | -$0.32 - -$0.17 | +11.54% | Beat | N/A | 6 | N/A | Feb 24, 2021 | $35.61M |
| Sep 30, 2020 | -$0.08 | -$0.09 | -$0.21 - $0.19 | +11.11% | Beat | -125.8% | 6 | N/A | Nov 4, 2020 | $74.33M |
| Jun 30, 2020 | $0.12 | -$0.06 | -$0.24 - $0.20 | +300.00% | Beat | -73.3% | 6 | N/A | Aug 4, 2020 | $71.69M |
| Mar 31, 2020 | -$0.07 | -$0.11 | -$0.12 - -$0.08 | +36.36% | Beat | -129.2% | 6 | N/A | May 5, 2020 | $126.86M |
| Dec 31, 2019 | -$0.06 | $0.10 | $0.08 - $0.15 | -160.00% | Miss | -113.6% | 6 | N/A | Feb 25, 2020 | $440.86M |
| Sep 30, 2019 | $0.31 | $0.22 | $0.21 - $0.28 | +40.91% | Beat | -57.5% | 7 | N/A | Nov 5, 2019 | $91.76M |
| Jun 30, 2019 | $0.45 | $0.49 | $0.41 - $0.63 | -8.16% | Miss | -30.8% | 7 | N/A | Aug 7, 2019 | $101.06M |
| Mar 31, 2019 | $0.24 | $0.33 | $0.17 - $0.40 | -27.27% | Miss | -50.0% | 7 | N/A | May 7, 2019 | $90.20M |
| Dec 31, 2018 | $0.44 | $0.25 | $0.20 - $0.35 | +76.00% | Beat | +41.9% | 7 | N/A | Feb 26, 2019 | $265.11M |
| Sep 30, 2018 | $0.73 | $0.53 | N/A | +37.74% | Beat | +121.2% | N/A | N/A | Nov 6, 2018 | $95.29M |
| Jun 30, 2018 | $0.65 | $0.44 | $0.42 - $0.49 | +47.73% | Beat | +71.1% | 7 | N/A | Aug 7, 2018 | $97.24M |
| Mar 31, 2018 | $0.48 | $0.29 | $0.17 - $0.36 | +65.52% | Beat | +77.8% | 6 | N/A | Apr 30, 2018 | $79.05M |
| Dec 31, 2017 | $0.31 | $0.23 | $0.18 - $0.29 | +34.78% | Beat | +24.0% | 6 | N/A | Feb 27, 2018 | $63.79M |
| Sep 30, 2017 | $0.33 | $0.29 | $0.24 - $0.33 | +13.79% | Beat | +106.3% | 6 | N/A | Nov 7, 2017 | $69.03M |
| Jun 30, 2017 | $0.38 | $0.28 | $0.24 - $0.32 | +35.71% | Beat | +52.0% | 6 | N/A | Aug 3, 2017 | $64.12M |
| Mar 31, 2017 | $0.27 | $0.14 | N/A | +92.86% | Beat | +145.5% | N/A | N/A | May 9, 2017 | $52.50M |
| Dec 31, 2016 | $0.25 | $0.11 | N/A | +127.27% | Beat | +31.6% | N/A | N/A | Feb 28, 2017 | $50.85M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.61, after -$0.87 the year before. It was $0.77 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.61 | N/A |
| Dec 31, 2024 | -$0.87 | N/A |
| Dec 31, 2023 | -$2.68 | N/A |
| Dec 31, 2022 | -$1.39 | N/A |
| Dec 31, 2021 | -$0.29 | N/A |
| Dec 31, 2020 | -$0.26 | -127.7% |
| Dec 31, 2019 | $0.94 | -59.1% |
| Dec 31, 2018 | $2.30 | +78.3% |
| Dec 31, 2017 | $1.29 | +67.5% |
| Dec 31, 2016 | $0.77 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,400 words across 4 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 2,378 | 4 | |
| 2026Q2 | Jun 30, 2026 | 4,522 | 7 | |
| 2026Q1 | Mar 31, 2026 | 4,103 | 6 | |
| 2025Q4 | Dec 31, 2025 | 5,582 | 6 | |
| 2025Q3 | Sep 30, 2025 | 3,484 | 6 | |
| 2025Q2 | Jun 30, 2025 | 4,368 | 7 | |
| 2025Q1 | Mar 31, 2025 | 3,031 | 8 | |
| 2024Q4 | Dec 31, 2024 | 5,096 | 5 |
2026Q3 Earnings Call
Opening remarks
Lorna Williams Senior Vice President of Investor Relations and Strategic Planning Thank you all for participating in today's call. Joining me are President and Chief Executive Officer, Andrew Reding, and Chief Financial Officer, Jason A. Richardson. Earlier today, Inogen released financial results for the third quarter of 2026. The earnings release is available in the Investor Relations section of the company's website along with the supplemental financial package. During today's call, we will be discussing non-GAAP financial measures that we believe will provide useful information for investors. The information is not intended to be considered in isolation or as a substitute for GAAP financial information. Reconciliations for these non-GAAP measures to the most directly comparable GAAP measures are included in today's earnings release and supplemental financial package, each of which is available in the Investor Relations section of our website. In addition, our discussion today will include forward-looking statements, including, but not limited to, expectations about our future financial and operating performance. We make these statements based on current expectations and reasonable assumptions. However, our actual results could differ due to risks and uncertainties. Please review our annual report and other SEC filings for a discussion of risk factors that could cause our actual results to differ materially from any forward-looking statements made today. Forward-looking statements made on today's call speak only as of today, and Inogen undertakes no obligation to update or revise these statements except as required by law. The company has not provided a reconciliation of forward-looking adjusted earnings metrics to the most directly comparable GAAP measures because certain items that impact net income are uncertain or outside the company's control and cannot be reasonably estimated without unreasonable effort. With that, I will turn the call over to Inogen's President and CEO, Andrew Reding.
Andrew Reding President and Chief Executive Officer Thank you, Lorna. Good afternoon, everyone, and thank you for being with us for Inogen's third quarter 2026 earnings call. I am pleased to speak to you today as Inogen's new CEO. Before I turn to the results, I would like to share why I joined Inogen and why I am excited about what lies ahead. I came to Inogen as chief operating officer in July, after more than 30 years in medical technology, including a number of years in respiratory care. The common thread throughout my career has been growth: building commercial organizations, bringing new products to market, and scaling businesses that make a difference in the lives of patients. Most recently, I spent more than six years as chief commercial officer of Viant Medical, where I led commercial teams as the company grew to 25 facilities and hundreds of medical device customers, including many of the industry's largest.
Frequently Asked Questions About INGN
Did INGN beat earnings estimates last quarter?
No. Inogen reported EPS of -$0.56 for the quarter ended Sep 30, 2026, below the -$0.06 estimate by 833.33%.
What EPS do analysts expect from INGN next quarter?
The consensus EPS estimate for Inogen for the quarter ending Dec 31, 2026 is -$0.18 from 4 analysts, with estimates from -$0.19 to -$0.17.
How often does INGN beat earnings estimates?
Inogen beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of -72.28%.
INGN pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts